NCT01104532已完成1 期
A Phase 1, Open Label, Randomized, Crossover, Drug Interaction Study of the Pharmacokinetics of ASP1941 and Sitagliptin After Separate and Concomitant Administration to Healthy Adult Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 64
- 主要终点
- Pharmacokinetic variables assessment through analysis of blood samples
研究概览
简要总结
The purpose of the study is to evaluate pharmacokinetics, pharmacodynamics and safety following the administration of ASP1941 and sitagliptin in single and multiple doses.
详细描述
All subjects will be enrolled at one center and confined to the unit for up to 17 days. Subjects will be dosed in the fasting state in one of the four groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subject weighs at least 50 kg, and has a body mass index (BMI) of 18 to 32 kg/m2 inclusive
- •The subject's 12-lead electrocardiogram (ECG) results are normal
- •The female subject must be at least two years postmenopausal, surgically sterile or practicing effective birth control and not pregnant or lactating
- •The male or female subject agrees to practice highly effective birth control from Screening until 7 days post last dose
排除标准
- •The subject has a history or evidence of any clinically significant cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy (excluding non-melanoma skin cancer)
- •The subject has evidence of renal insufficiency (serum creatinine ≥ 1.5 in men and ≥ 1.3 in women)
- •The subject has a history of cholelithiasis or acute pancreatitis
- •The subject has any condition possibly affecting drug absorption (e.g., gastrectomy)
- •The subject has history of consuming more than 14 units of alcoholic beverages per week within last 6 months or has a history of alcoholism or drug/chemical/substance abuse within past 2 years or the subject tests positive for alcohol or drugs of abuse
- •The subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to clinic check-in
- •The subject has a supine mean systolic blood pressure <90 or >160 mm/Hg and a mean diastolic blood pressure <50 or >90, or pulse rate higher than 100 beats per min (bpm)
- •The subject has a 12-lead ECG demonstrating QTcF >470 msec (female) or >450 msec (male)
- •The subject is known positive for human immunodeficiency virus (HIV) antibody
- •The subject has a positive test for tuberculosis (TB), hepatitis C antibody, or positive for hepatitis B surface antigen (HGsAg)
- •The subject has used prescription or non-prescription drugs within 14 days or 5 half-lives (whichever is longer) or complementary and alternative medicines (CAM) within 14 days prior to study drug administration (excluding oral contraceptives, hormone replacement therapy [HRT], and acetaminophen)
- •The subject has been vaccinated within the last 7 days
- •The subject has had any significant blood loss, donated one unit (450 mL) or blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission
研究组 & 干预措施
Dosing Regimen 1
Experimental
干预措施: ASP1941 (Drug)
Dosing Regimen 1
Experimental
干预措施: sitagliptin (Drug)
Dosing Regimen 2
Experimental
干预措施: ASP1941 (Drug)
Dosing Regimen 2
Experimental
干预措施: sitagliptin (Drug)
Dosing Regimen 3
Experimental
干预措施: ASP1941 (Drug)
Dosing Regimen 3
Experimental
干预措施: sitagliptin (Drug)
Dosing Regimen 4
Experimental
干预措施: ASP1941 (Drug)
Dosing Regimen 4
Experimental
干预措施: sitagliptin (Drug)
结局指标
主要结局
Pharmacokinetic variables assessment through analysis of blood samples
时间窗: Day 1 to Day 15
次要结局
- Pharmacodynamic variables assessment through analysis of blood and urine samples(Day -1 and up to Day 11)
- Safety assessed by recording of adverse events, laboratory assessments, electrocardiograms (ECGs), vital signs and physical examinations(Day 1 through scheduled group check out (Day 11 and up to Day 15) or early termination.)
研究者
相似试验
已完成
1 期
A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy SubjectsHealthyPharmacokinetics of ASP1941NCT01088919Astellas Pharma Inc64
已完成
1 期
An Open-Label Study of Two Formulations of LX1033 in Healthy Human SubjectsIrritable Bowel SyndromeNCT01411800Lexicon Pharmaceuticals28
已完成
1 期
Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male VolunteersPrimary HypercholesterolemiaNCT02941848Hanmi Pharmaceutical Company Limited60
已完成
1 期
Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy VolunteersHealthyMultiple SclerosisNCT01610310Biogen55
已完成
1 期
Single Dose Study Of The Effect Of Cyclosporine On The Pharmacokinetics Of PF-04991532 In Health VolunteersHealthyDrug InteractionNCT01370343Pfizer12